Citadel Advisors’s Stemline Therapeutics, Inc. STML Stock Holding History

Citadel Advisors’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-10,100	Closed	-$49K	–	10886
2020 Q1	$49K	Buy	+10,100	New	+$65.5K	﹤0.01%	9042
2017 Q4	–	Sell	-10,100	Closed	-$112K	–	8665
2017 Q3	$112K	Buy	+10,100	New	+$95K	﹤0.01%	7001
2016 Q1	–	Sell	-300	Closed	-$2K	–	8516
2015 Q4	$2K	Buy	+300	New	+$2.43K	﹤0.01%	8591
2015 Q3	–	Sell	-32,600	Closed	-$384K	–	9411
2015 Q2	$384K	Sell	32,600 -3,200	-9%	-$44.4K	﹤0.01%	5385
2015 Q1	$518K	Buy	35,800 +20,400	+132%	+$312K	﹤0.01%	4858
2014 Q4	$263K	Buy	15,400 +9,800	+175%	+$141K	﹤0.01%	5624
2014 Q3	$70K	Buy	+5,600	New	+$68.9K	﹤0.01%	6674

Citadel Advisors's STML Position: Q2 2020 in Review

Citadel Advisors sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 88,520 shares — an estimated $429K sold.

Citadel Advisors first reported a position in STML in Q3 2013 and held it in 15 quarters. The position peaked at $15M in Q3 2018. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.

Citadel Advisors reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
Citadel Advisors sold 88,520 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $429K.
Citadel Advisors first reported a position in Stemline Therapeutics, Inc. in Q3 2013 and held it in 15 quarters.
Citadel Advisors's Stemline Therapeutics, Inc. position peaked at $15M in Q3 2018.
0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.

Based on Citadel Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.